奥沙利铂、伊立替康联合5-氟尿嘧啶、亚叶酸治疗转移或复发胃癌的临床疗效及不良反应观察

Clinical efficacy and adverse reactions of oxaliplatin,irinotecan combined with 5-fluorouracil,folinic acid in the treatment of metastasis or recurrence of gastric cancer

目的观察奥沙利铂(L-OHP)、伊立替康联合5-氟尿嘧啶(5-Fu)、亚叶酸(FA)治疗胃癌转移或复发患者的临床疗效及不良反应。方法 33例胃癌转移或复发患者,第1、8、15、22天,伊立替康70 mg/m2,静脉滴注1 h,奥沙利铂50 mg/m2,静脉滴注2 h,亚叶酸500 mg/m2,静脉滴注2 h后,5-氟尿嘧啶2 000 mg/m2,静脉滴注24 h,每36 d重复1次。结果无完全缓解病例,部分缓解18例。主要不良反应为贫血、中性粒细胞减少、便秘、周围神经病变。无治疗相关死亡病例。结论奥沙利铂、伊立替康联合5-氟尿嘧啶、亚叶酸治疗胃癌转移或复发患者疗效较好,不良反应较轻。

Objective To observe the efficacy and safety of the combination of oxaliplatin, irinotecan, 5-fluorouracil （5-FU）, and folinic acid （FA） as first-line chemotherapy for patients with metastatic or recurrent gastric cancer. Meth- ods 33 patients with metastatic or recurrent gastric cancer underwent chemotherapy. The chemotherapy regimen consis- ted of irinotecan 70 mg/m2 , oxaliplatin 50 mg/m2 , FA 500 mg/m2 and 5-FU 2 000 mg/m2 on days 1, 8, 15 and 22, repeated from day 36. Results Of the 33 patients, No patient achieved complete remission and 18 patients achieved partial remisson. The main adverse reaction were anemia, neutropenia, constipation and peripheral neuropathy. No treatment-related death was reported. Conclusion This study shows that combination chemotherapy with oxaliplatin, iri- notecan, 5-FU, and FA is an active and well-tolerated regimen as first-line treatment in patients with metastatic or recurrent gastric cancer.